Table 3 Univariate analysis of clinicopathological characteristics on the patient’s risk groups

Gender

0.009

Male (27.4%)

43 (24.7%)

47 (24.4%)

29 (42.6%)

Female (72.6%)

131 (75.3%)

146 (75.6%)

39 (57.4%)

Age of diagnosis (years)

Mean age (±SD), year

46.7 (±12.0)

46.5 (±12.2)

40.3 (±11.3)

0.001

<45 years

75 (43.1%)

81 (42.0%)

45 (66.2%)

0.002

≥45 years

99 (56.9%)

112 (58.0%)

23 (33.8%)

Primary tumor size

Mean size (±SD), cm

1.02 (±0.73)

1.30 (±1.07)

1.58 (±1.47)

0.03

≤1 cm

114 (65.5%)

117 (60.6%)

33 (48.5%)

0.052

>1 cm

60 (34.5%)

76 (39.4%)

35 (51.5%)

PTC variant

0.04

Classic

128 (73.6%)

162 (83.9%)

54 (79.4%)

Follicular v.

14 (8.0%)

9 (4.7%)

0 (0%)

Tall cell v.

19 (10.9%)

9 (4.7%)

5 (7.4%)

Diffuse sclerosing v.

1 (0.6%)

2 (1.0%)

2 (2.9%)

Others

12 (6.9%)

11 (5.7%)

7 (10.3%)

Multiplicity

0.429

(−)

78 (44.8%)

75 (38.9%)

31 (45.6%)

(+)

96 (55.2%)

118 (61.1%)

37 (54.4%)

Extrathyroidal extension

0.001

Absent (35.3%)

77 (44.3%)

69 (35.8%)

28 (41.2%)

Present (64.7%)

97 (55.7%)

124 (64.2%)

40 (58.8%)

Minimally

86 (88.7%)

100 (80.6%)

36 (90.0%)

0.161

Grossly

11 (11.3%)

24 (19.4%)

4 (10.0%)

Mean number of mLN

1.88 (±1.12)

5.25 (±4.81)

8.12 (±4.51)

0.001

T stage

0.035

T1

79 (45.4%)

63 (32.6%)

23 (33.8%)

T2

2 (1.1%)

5 (2.6%)

5 (7.4%)

T3

92 (52.9%)

124 (64.2%)

40 (58.8%)

T4a

1 (0.6%)

1 (0.5%)

0 (0%)

BRAF mutation

0.291

Absent (12.9%)

27 (15.5%)

22 (11.4%)

6 (8.8%)

Present (87.1%)

147 (84.5%)

171 (88.6%)

62 (91.2%)

Stimulation Tg

Mean sTg (±SD), ng/ml

1.24 (±3.92)

2.50 (±7.79)

3.83 (±7.62)

0.001

<1 ng/ml

142 (81.6%)

145 (75.1%)

38 (55.9%)

<0.001

≥1 ng/ml

32 (18.4%)

48 (24.9%)

30 (44.1%)